Clinical study
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control

https://doi.org/10.1016/S0735-1097(01)01555-8Get rights and content
Under an Elsevier user license
open archive

Abstract

OBJECTIVES

This study was designed to determine whether blood thrombogenicity is related to chronic glycemic control in type 2 diabetes mellitus (T2DM).

BACKGROUND

Type 2 diabetes mellitus is associated with accelerated atherosclerosis and a high rate of arterial thrombotic complications. Whether increased blood thrombogenicity is associated with glycemic control has not been properly tested.

METHODS

Forty patients with T2DM with hemoglobin A1c (HbA1c) ≥7.5% were selected. Maintaining their current hypoglycemic therapies, patients were randomized into a conservative (diet modification plus placebo) or intensive (diet modification plus troglitazone) hypoglycemic regimen for three months. Blood thrombogenicity was measured at baseline and after three months with the Badimon ex vivo perfusion chamber and assessed as platelet-thrombus formation. The repeated measurements allowed every patient to be his/her own control.

RESULTS

Patients in both groups (48% and 74% of the conservative and intensive groups, respectively) improved glucose control (HbA1c reduction ≥0.5%), showing a significant decrease in blood thrombogenicity. A significant positive correlation was observed between the reduction in thrombus formation and the reduction in HbA1c (r = 0.47, p < 0.01). The reduction in HbA1c achieved by both treatments was comparable. Patients without glycemic improvement showed no change in blood thrombogenicity. Improved glycemic control was the only significant predictor of a decrease in blood thrombogenicity.

CONCLUSIONS

In T2DM, there is an association between improved glycemic control and blood thrombogenicity reduction. The effect of glycemic control on the thrombotic complications of T2DM patients deserves further investigation.

Abbreviations

ANOVA
analysis of variance
CRP
C-reactive protein
HbA1c
hemoglobin A1c
MANOVA
multivariate analysis of variance
PAI-1
plasminogen activator inhibitor 1
RM-ANOVA
repeated measures ANOVA
T2DM
type 2 diabetes mellitus

Cited by (0)

This study was supported by a grant from the Spanish Society of Cardiology, Madrid, Spain (JIO), the National Institutes of Health (Bethesda, Maryland) grant NIH-P50HL54467-SCOR in thrombosis to Dr. Juan J. Badimon, the National Center for Research Resources (5M01RR0071) (Bethesda, Maryland) and from Pfizer (Morris Plains, New Jersey).